Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.

Lux, MP; Wöckel, A; Benedict, A; Buchholz, S; Kreif, N; Harbeck, N; Kreienberg, R; Kaufmann, M; Beckmann, MW; Jonat, W; +7 more... Hadji, P; Distler, W; Raab, G; Tesch, H; Weyers, G; Possinger, K; Schneeweiss, A; (2010) Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system. Onkologie, 33 (4). pp. 155-66. ISSN 0378-584X DOI: https://doi.org/10.1159/000286233

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1159/000286233

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar